Age 18~75 years old;
ECOG physical status score 0-1 points;
Head squamous cell carcinoma (HNSCC) diagnosed by histology or cytology, the primary site is oral cavity, oral cavity Throat, lower throat or throat;
Recurrent and/or metastatic HNSCC without indications for local radical treatment;
According to the evaluation criteria for the efficacy of solid tumors (RECIST version 1.1), there is at least one measurable lesion, right For lesions that have received radiotherapy in the past, only if there is clear disease progression 3 months after the end of radiotherapy, can it be Was selected as the target lesion;
There are a large number of tumor tissue samples for PD-L1 immunohistochemical detection;
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Appendix 4C Quarterly Activity Report
Mesoblast LimitedApril 30, 2021 GMT
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its pipeline of late-stage product candidates, and an activity report for the third quarter ended March 31, 2021.
“We are very excited about the top-line results announced today from the trial of remestemcel-L in patients on mechanical ventilation due to COVID-19. These showed that remestemcel-L reduced mortality through 60 days in the pre-specified population under 65 years old, particularly when used with dexamethasone as part of standard of care. This has the potential to make a substantial impact in outcomes for this critical patient population,” said Silviu Itescu, Chief Executive of Mesoblast.
email article
Patients with secondary mitral regurgitation (MR) who were left with high gradients after a MitraClip procedure were not inherently at a disadvantage in their subsequent clinical outcomes, according to a COAPT analysis.
MitraClip-treated trial participants, divided into quartiles by mitral valve gradient (MVG) on discharge, shared similar odds of combined all-cause mortality and heart failure hospitalization at 2 years (
P=0.78):
Q2 (3.0 mm Hg; n=61): 49.2%
Q3 (4.2 mm Hg; n=62): 40.6%
Q4 (7.2 mm Hg; n=64): 40.9%
These findings persisted after adjustment for baseline clinical and echocardiographic characteristics, post-procedure MR grade, and number of clips implanted, reported Howard Herrmann, MD, of the Hospital of the University of Pennsylvania in Philadelphia, and colleagues in
(1)
BERLIN and ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) BERLIN HEALS, a company dedicated to developing and offering novel and life-saving treatments for patients suffering from heart failure, announces results of a first-in-human study published in
ESC Heart Failure, in patients with dilated cardiomyopathy for its proprietary C-MIC device. The C-MIC is a small implantable device that delivers a minimal constant electrical DC current to the heart. The results show significant, rapid improvements in heart function, heart size and quality of life of patients. Thus, this treatment has the potential to become the first sustainable, almost curative, treatment for heart failure in patients with unmet medical needs.
Delirium Common, Costly After Mitral, Tricuspid Valve Repair medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.